tiprankstipranks
Trending News
More News >
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
US Market
Advertisement

ALX Oncology Holdings (ALXO) Earnings Dates, Call Summary & Reports

Compare
423 Followers

Earnings Data

Report Date
Mar 05, 2026
After Close (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.33
Last Year’s EPS
-0.55
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 07, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call presented strong clinical results for evorpacept and promising progress for ALX2004. The company is well-funded and advancing its pipeline with optimism. However, there are challenges related to market positioning and historical concerns with ADCs that need addressing.
Company Guidance
During the Q3 2025 call, the company highlighted key metrics and progress in their clinical programs, notably the ASPEN-06 trial which demonstrated CD47 expression as a predictive biomarker for evorpacept's efficacy in HER2-positive gastric cancer. The trial showed a 41% objective response rate (ORR) in the evorpacept arm versus 27% in the control arm, with CD47 high-expression patients exhibiting a 65% ORR compared to 26% in the control group, underscoring the potential of CD47 as a biomarker. The median progression-free survival (PFS) was 18.4 months in the treatment arm versus 7 months in the control, with an overall survival (OS) of 17 months compared to 10 months in the control arm, highlighting a hazard ratio of 0.39 for PFS and 0.63 for OS. The company's financials were strong, with a cash balance of $67 million, providing a runway into Q1 2027. They are advancing their Phase II breast cancer trial, targeting a 35-40% ORR, and progressing with the ALX2004 EGFR-targeted ADC in Phase I trials, with initial safety data expected in 2026.
Evorpacept's Positive Clinical Trial Results
Evorpacept showed a significant benefit in HER2-positive gastric cancer patients with high CD47 expression, achieving a 65% ORR in the treatment arm versus 26% in control, and a median PFS of 18.4 months compared to 7 months in control.
Strong Financial Position
The company reported a total cash balance of $67 million, expected to provide runway into the first quarter of 2027.
ALX2004 Clinical Progress
The EGFR-targeted ADC, ALX2004, is progressing well in clinical trials, with the first dose cohort completed without any DLT and currently dosing in the second cohort.

ALX Oncology Holdings (ALXO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ALXO Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 05, 2026
2025 (Q4)
-0.33 / -
-0.55
Nov 07, 2025
2025 (Q3)
-0.37 / -0.36
-0.5837.07% (+0.21)
Aug 12, 2025
2025 (Q2)
-0.42 / -0.49
-0.7635.53% (+0.27)
May 08, 2025
2025 (Q1)
-0.46 / -0.58
-0.7118.31% (+0.13)
Mar 06, 2025
2024 (Q4)
-0.67 / -0.55
-0.9340.86% (+0.38)
Nov 07, 2024
2024 (Q3)
-0.78 / -0.58
-1.2453.23% (+0.66)
Aug 08, 2024
2024 (Q2)
-0.75 / -0.76
-0.849.52% (+0.08)
May 09, 2024
2024 (Q1)
-0.82 / -0.71
-0.744.05% (+0.03)
Mar 07, 2024
2023 (Q4)
-0.88 / -0.93
-0.75-24.00% (-0.18)
Nov 13, 2023
2023 (Q3)
-0.85 / -1.24
-0.87-42.53% (-0.37)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ALXO Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 07, 2025
$1.18$1.38+16.95%
Aug 12, 2025
$0.62$0.66+6.45%
May 08, 2025
$0.48$0.46-4.17%
Mar 06, 2025
$1.31$1.06-19.08%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ALX Oncology Holdings (ALXO) report earnings?
ALX Oncology Holdings (ALXO) is schdueled to report earning on Mar 05, 2026, After Close (Confirmed).
    What is ALX Oncology Holdings (ALXO) earnings time?
    ALX Oncology Holdings (ALXO) earnings time is at Mar 05, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ALXO EPS forecast?
          ALXO EPS forecast for the fiscal quarter 2025 (Q4) is -0.33.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis